A pleasant Friday morning to you! Adam Feuerstein, here, reporting from the Pharmalittle campus, temporarily relocated to Cambridge, Mass., as your regular New Jersey host Ed takes the day off. Like the one-and-only Mr. Pharmalot, I enjoy my daily headlines with a hot cup of joe. Have a great weekend.
Italian pharma company Recordati said it will buy from Sanofi the global rights to an approved drug to treat cold agglutinin disease, a rare autoimmune disorder, for $825 million, Reuters reports.
The Medicare Advantage market is expected to grow in 2025, despite big changes from insurers, STAT reports. Health insurance companies will still offer older adults a lot of plan choices with low, or completely free, premiums. However, insurers have made important but subtle tweaks to next year’s plans that will force millions of members to shell out more for their prescription drugs and overall medical care than they do currently.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
